Introduction: Detection and enumeration of malignant plasma cells at the time of stem cell collection
prior to autologous stem cell transplantation identifies patients with high risk of
progression. There is a rising demand for introduction of highly standardized, rapid
and sensitive assays for minimal residual disease (MRD) testing to improve quality
control of cellular products and patient monitoring.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
